SMS Pharmaceuticals Ltd reported a 76.4% year-on-year (YoY) jump in its consolidated net profit to ₹25.14 crore for the quarter ended September 30, 2025, compared to ₹14.25 crore in the same period last year.

The company’s revenue from operations rose 23.2% YoY to ₹242.4 crore from ₹196.7 crore, driven by healthy demand across key segments. EBITDA for the quarter came in at ₹48.34 crore, up 51.8% from ₹31.85 crore in the year-ago period, while the EBITDA margin improved to 19.94% from 16.19% a year ago, indicating better cost efficiencies and improved product mix.

In a separate regulatory filing, the Hyderabad-based company said there was no deviation or variation in the utilisation of funds raised through its preferential issue. The company had allotted 90 lakh convertible warrants in

See Full Page